Phase 3 Readout

MBRX: Phase 3 Topline: A Pivotal Phase 2/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Stu

Name: Phase 3 Topline: A Pivotal Phase 2/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Stu
Start: 2030-08-01
End: 2030-08-01

August 1, 2030 · cytarabine. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: August 1, 2030
Company: Moleculin Biotech, Inc. (MBRX)
Drug: cytarabine

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Pivotal Phase 2/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Stu

August 1, 2030

MBRX overview →

Company: Moleculin Biotech, Inc. (MBRX)
Drug: cytarabine
Indication: Acute Myeloid Leukaemia (AML)